Trial Profile

An Open Label, Dose Escalation Study to Evaluate the Safety and Efficacy of Localized Injection of STP705 in Adult Patients With Basal Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 02 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs STP 705 (Primary) ; STP 705 (Primary)
Indications Basal cell cancer; Carcinoma
Focus Therapeutic Use
Sponsors Sirnaomics

Most Recent Events

28 Mar 2024 According to Sirnaomics media release, the Company will hold the End-of-Phase II meeting with the U.S. FDA to obtain guidance on the future path forward for the late-stage development of STP705 for the treatment of BCC
15 Mar 2024 Status changed from active, no longer recruiting to completed.
15 Mar 2024 Number of treatment arms increased from 3 to 7 by the addition of separate arms for the doses 120, 180, 240 and 320 micrograms.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com